becker

Servier faces major setback as pivotal clinical trial for Becker muscular dystrophy drug fails to meet primary endpoints

The French pharmaceutical giant Servier announced on Tuesday that its experimental therapy, sevasemten, failed to demonstrate a statistically significant benefit…